top of page

EC approval for Afinitor for the treatment of neuroendocrine tumours

The European Commission has approved Novartis’ Afinitor (everolimus) tablets for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumours (NET) of gastrointestinal (GI) or lung origin in adults with progressive disease.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page